Cargando…

In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma

PURPOSE: Ac-225 labeled with prostate-specific membrane antigen (PSMA-617), a transmembrane glycoprotein which is highly expressed in prostate carcinoma cells, is presently being considered a promising agent of targeted alpha therapy for the treatment of patients suffering from metastatic castration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakral, Parul, Simecek, Jakub, Marx, Sebastian, Kumari, Jyotsna, Pant, Vineet, Sen, Ishita Barat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320836/ https://www.ncbi.nlm.nih.gov/pubmed/34385780 http://dx.doi.org/10.4103/ijnm.ijnm_200_20

Ejemplares similares

Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

Efficacy and Safety of (225)Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Ma, Jiao, et al.
Publicado: (2022)

CKD After 225Ac-PSMA617 Therapy in Patients With Metastatic Prostate Cancer
por: Pelletier, Karyne, et al.
Publicado: (2020)

Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022)

(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
por: Sathekge, Mike, et al.
Publicado: (2018)

The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning
por: Agrawal, Sumit
Publicado: (2020)

Rare Sites of Metastases in Prostate Cancer Detected on Ga-68 PSMA PET/CT Scan—A Case Series
por: Dureja, Sugandha, et al.
Publicado: (2017)

Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer
por: Meyer, Catherine, et al.
Publicado: (2023)

Treatment of Prostate Cancer with CD46-targeted (225)Ac Alpha Particle Radioimmunotherapy
por: Bidkar, Anil P., et al.
Publicado: (2023)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of (225)Ac-PSMA (Prostate-Specific Membrane Antigen)
por: Belli, Maria Luisa, et al.
Publicado: (2020)

Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer
por: Satapathy, Swayamjeet, et al.
Publicado: (2020)

Radiation Dose to the Occupational Worker during the Synthesis of (188)Re-labeled Radiopharmaceuticals in the Nuclear Medicine Department
por: Thakral, Parul, et al.
Publicado: (2018)

(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
por: Sathekge, Mike, et al.
Publicado: (2023)

Incremental Value of Ga-68 Prostate-Specific Membrane Antigen-11 Positron-Emission Tomography/Computed Tomography Scan for Preoperative Risk Stratification of Prostate Cancer
por: Pallavi, UN, et al.
Publicado: (2020)

Efficacy and Safety of [(225)Ac]Ac-PSMA-617 Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
por: Rosar, Florian, et al.
Publicado: (2021)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

AB225. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer
por: Wang, T, et al.
Publicado: (2014)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy
por: Rosar, Florian, et al.
Publicado: (2021)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
por: Maman, Adem
Publicado: (2023)

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy
por: Cędrowska, Edyta, et al.
Publicado: (2018)

Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors - safety at curative doses
por: Cheal, Sarah M., et al.
Publicado: (2020)

The Role of PET-CT-Guided Metabolic Biopsies in Improving Yield of Inconclusive Anatomical Biopsies: A Review of 5 Years in a Teaching Hospital
por: Malik, Dharmender, et al.
Publicado: (2023)

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
por: Sathekge, Mike, et al.
Publicado: (2022)

Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
por: Groener, Daniel, et al.
Publicado: (2021)

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
por: Wrenger, Robin, et al.
Publicado: (2022)

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Comparison of the biodistribution of $^{225}$Ac and radiolanthanides as citrate complexes
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1990)

The application of poorly crystalline silicotitanate in production of (225)Ac
por: Fitzsimmons, Jonathan, et al.
Publicado: (2019)

Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
por: Robertson, Andrew Kyle Henderson, et al.
Publicado: (2018)

Resonant laser ionization and mass separation of (225)Ac
por: Johnson, Jake D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_grdefsjk1ee2mke5nlgtnmdrnc